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Abstract
Rett syndrome (RTT) is an autism spectrum disorder mainly caused by mutations in the X-
linkedMECP2 gene and affecting roughly 1 out of 10.000 born girls. Symptoms range in
severity and include stereotypical movement, lack of spoken language, seizures, ataxia
and severe intellectual disability. Notably, muscle tone is generally abnormal in RTT girls
and women and theMecp2-null mouse model constitutively reflects this disease feature.
We hypothesized that MeCP2 in muscle might physiologically contribute to its development
and/or homeostasis, and conversely its defects in RTT might alter the tissue integrity or
function. We show here that a disorganized architecture, with hypotrophic fibres and tissue
fibrosis, characterizes skeletal muscles retrieved fromMecp2-null mice. Alterations of the
IGF-1/Akt/mTOR pathway accompany the muscle phenotype. A conditional mouse model
selectively depleted ofMecp2 in skeletal muscles is characterized by healthy muscles that
are morphologically and molecularly indistinguishable from those of wild-type mice raising
the possibility that hypotonia in RTT is mainly, if not exclusively, mediated by non-cell auton-
omous effects. Our results suggest that defects in paracrine/endocrine signaling and, in par-
ticular, in the GH/IGF axis appear as the major cause of the observed muscular defects.
Remarkably, this is the first study describing the selective deletion ofMecp2 outside the
brain. Similar future studies will permit to unambiguously define the direct impact of MeCP2
on tissue dysfunctions.
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Introduction
Rett syndrome (RTT; MIM 312750) is a genetic disorder that because of its prevalence (roughly
1/10.000 born girls) is considered one of the most frequent causes of intellectual disability in
females worldwide [1]. Typical RTT patients appear to develop normally throughout the first
6–18 months of life, when neurological development arrests and a regression phase occurs,
leading to the loss of previously acquired skills. During and after the regression phase, patients
develop typical symptoms including continuous stereotypic hand movements with a decline of
purposeful hand use, loss of language skills, the appearance of autistic features, gait abnormali-
ties, breathing irregularities, seizures, scoliosis and autonomic dysfunctions [2]. Mild general-
ized hypotonia is frequently observed in the first months of life of RTT patients, when
symptoms are not yet overt. Moreover, an abnormal muscle tone is generally observed at later
times [3]. Accordingly, abnormal muscle tone is a supportive criterion for the clinical diagnosis
of atypical RTT [3].
Most girls affected by RTT carry de novomutations in the X-linkedMECP2 gene [4]. The
causative role ofMECP2 in RTT has been further supported by mouse models carryingMecp2
alterations [5].Mecp2-null males (Mecp2-/y) have no apparent phenotype up to 3–8 weeks of
age, when they develop gross abnormalities, such as locomotor defects, hindlimb clasping,
tremors, breathing abnormalities, seizures, reduced spontaneous movements and severe hypo-
tonia. Symptoms worsen over time and the animals die within 6–10 weeks of age [5].
SinceMECP2 codes for an epigenetic transcriptional regulator that, although ubiquitously
expressed, is particular abundant in brain [6] and since RTT has always been considered a
pediatric neurological condition, conditional knock-out mice have been generated in order to
understand the role ofMecp2 in discrete brain regions or cell types. Overall, these studies have
supported the contention that RTT is mainly, if not exclusively, a neuronal disease. However,
the demonstration of increased glial gene expression in post-mortem female RTT brains and
an altered glial metabolism inMecp2mouse models [7] have prompted the study of a possible
role of glia in MeCP2-related conditions. It has been demonstrated thatMecp2-null astrocytes
affect neuronal growth and health in vitro and mouse breathing and locomotor activity in vivo
[7]. Further, a role for microglia in RTT has been suggested by the benefit of transplanting
wild-type bone marrow stem cells into irradiated youngMecp2-null mice [8]. Although no
conditional mouse models inactivatingMecp2 in organs different from brain have yet been
generated, a role for MeCP2 in the development of heart and skeleton has been proposed [9].
In light of these considerations and of the severe hypotonia affecting RTT patients and
mice, we investigated whether MeCP2 expression is required for the development and homeo-
stasis of the skeletal muscle using two mouse models. The results demonstrate that the muscle
of theMecp2-null mouse suffers of a severe hypotonia that is not directly mediated by the lack
of MeCP2 in this tissue.
Results
MeCP2 deficiency determines severe skeletal muscle atrophy and the
deregulation of the IGF/AKT signaling pathway
Mecp2-null mice show evident muscle hypotonia, postural defects and locomotor deficits. To
investigate possible skeletal muscle defects associated with these features, we initially verified
the integrity and the structure of the tissue. We retrieved muscles and other organs from 6
weeks oldMecp2-/y mice [10] and wild-type (WT) littermates.Mecp2-null muscles analyzed
were much smaller than those of WT littermates (39.2% to 49.5% weight reduction ± s.e.m.,
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Fig 1A and 1B). The reduction is in line with the overall reduced body weight of thisMecp2
mouse model (Fig 1A and 1B).
To investigate the overall organization of theMecp2-null muscle, we analyzed the histologi-
cal and histochemical features of the tissue after staining of muscle sections with Hematoxilin
& Eosin. As shown in Fig 1C,Mecp2-null skeletal muscles are characterized by a disrupted
architectural structure (Fig 1C). No necrotic or regenerating centronucleated fibers were
observed, indicating that RTT muscles are not dystrophic. Muscle fibers lacking MeCP2 have a
reduced cross section area (CSA), which is consistent with reduced muscle mass (Fig 1D and
1E). Sirius Red staining (Fig 1F and 1G) and collagen I mRNA expression (Fig 1H) indicate a
tendency of increased accumulation of fibrotic tissue inMecp2-null muscles, even if not statisti-
cally significant.
Most skeletal muscles contain a mixture of different types of myofibers; in particular, type I
myofibers are slow twitch, and fatigue resistant, whereas type II are fast twitch, either moder-
ately fatigue-resistant (IIA) or not fatigue-resistant (IIB). To address whetherMecp2 deficiency
might affect fiber-type composition we tested immunoreactivity to myosin heavy chain I
(MHCI) and IIb (MHCIIB), respectively used as markers of slow and fast fibers. Analyses were
performed in adult gastrocnemii; as shown in S1 Fig, no difference was revealed.
Muscle atrophy in the absence of overt necrosis could be caused by abnormal innervation
and/or functioning of the neuromuscular plaque. The number, shape and density of the neuro-
muscular junctions are comparable between WT andMecp2-/y mice at 5 weeks of age, as
assessed by immunofluorescence (S2 Fig), suggesting that the overall morphology of the neuro-
muscular plaque is maintained in the absence of MeCP2. This is in accordance with earlier
studies demonstrating that in RTT subjects motor action potentials could be evoked easily fol-
lowing electromagnetic stimulation of the motor cortex [11], therefore confirming that inner-
vation is functional.
The deregulation of signaling pathways involved in myofiber maintenance and homeostasis
and in the balance between protein synthesis and degradation could underlie muscle hypotro-
phy. Insulin-like Growth Factor 1 (IGF1) in particular has been suggested as a therapeutic
agent for RTT [12–15] and clinical trials are ongoing in patients; further, MeCP2 affects pro-
tein synthesis and the AKT/mTOR pathway in brain [16]. Accordingly, we demonstrate that
IGF1 mRNA expression is down regulated inMecp2-null muscles retrieved from 6 weeks old
mice (Fig 2A, P<0.0001) while the levels of the IGF1-receptor are unaffected (Fig 2A). IGF-1
protein expression is significantly reduced inMecp2-/y mice, both in the blood and in the mus-
cle (Fig 2B, P = 0.0313, P = 0.0096, respectively). The expression of phosphorylated ribosomal
protein S6 (P-rpS6), involved in protein synthesis and down-regulated in brains of MeCP2
defective mice and in human neurons derived from iPS cells [16,17], is also lower in MeCP2
deficient muscles with respect to wild-type controls (Fig 2C).
Although neurotrophins are best known for their functions in regulating neuronal survival,
plasticity and growth, it is now evident that they play important roles in several tissues. Among
these, skeletal muscle is an abundant source of neurotrophic support during development and
expresses several neurotrophin receptors, providing the basis for neurotrophin signaling in
skeletal muscle [18]. In particular, BDNF is expressed in skeletal muscle under various physio-
logical and pathological conditions [19], where it affects proliferation and differentiation of pri-
mary mioblasts and myotube size [20]. A functional interaction between MeCP2 and BDNF in
brain has been demonstrated, leading to a reduced expression of BDNF in the brain ofMecp2
mutant mice [21]. Thus, we addressed whether the neurotrophin expression might be also
altered inMecp2-null muscles. Here we show that the expression of Bdnf is significantly
reduced in muscles of 6 weeks oldMecp2-null mice (Fig 2D)
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MeCP2 deficiency affects muscle fiber growth during regeneration
To analyze whether MeCP2 expression is required for regeneration of adult muscle, we acutely
injured the tissue by injecting gastrocnemius or quadriceps muscles of 6 weeks oldMecp2-/y
mice and WT littermates with cardiotoxin (Ctx). Muscles were dissected 2, 5 and 10 days after
injury and processed for either histology or mRNA expression analysis. The regeneration pro-
cess was similar in WT and mutant mice, with transient infiltration of the tissue by inflamma-
tory leukocytes, appearance of regenerating centronucleated myofibers and timely disposal of
necrotic debris (Fig 3A, top panels). CSA of regenerating myofibers was significantly lower in
injured muscles ofMecp2-/y mice compared to WT littermates both 5 and 10 days after damage
(Fig 3A, bottom panels; 3B). These results indicate that also during regeneration fiber growth is
affected by MeCP2 deficiency.
Macrophages (MPs) are the major infiltrating population of phagocytes in the injured mus-
cle and are an important source of cytokines, chemokines and growth factors. Immunohisto-
chemical analyses ofMecp2-null and WT regenerating muscles from 6 weeks old mice indicate
that the extent of macrophage infiltration and the number of macrophages expressing markers
of conventional or alternative activation (CD86 or CD206, respectively) are similar (Fig 3C).
However, the expression profile of cytokines and macrophage specific enzymes induced by
injury differs between the two genotypes. In particular, MeCP2 deficiency, while not affecting
the level of expression of the inflammatory markers IL6, TNF-α, iNOS and IL10, alters their
kinetic of activation, generally delaying it (Fig 3D). Conversely, levels of IGF-1 remain consis-
tently lower inMecp2-/y muscles, confirming that lack of MeCP2 is associated with IGF-1 defi-
ciency (Fig 3D).
Muscles specifically ablated forMecp2 do not show growth defects
So far, our results suggest that fiber growth is affected in the absence of MeCP2; however, they
do not permit to address whether the observed phenotype is cell- or non cell-autonomous. To
get insight into the muscle-specific role of MeCP2, we crossed heterozygousMecp2flox/+ female
mice [10,22] withMyoDiCre males [23] thus obtaining mice with the deletion ofMecp2 in all
myoblasts and muscle fibers.Mecp2flox/y;MyoDiCre mice do not spontaneously develop RTT
and are fertile. WB analyses confirmed that muscles of adultMecp2flox/y;MyoDiCre mice do not
express MeCP2, while the expression is conserved in other organs and tissues. In accordance
with a previous publication, we observed reduced MeCP2 expression inMecp2flox animals (Fig
4A) [24].
Histological and morphometrical analyses, performed on 5 months old mice, revealed that
Mecp2flox/y;MyoDiCre TA muscles have normal structure and myofibers, and comparable CSA
with respect to control littermates (Fig 4B and 4C). IGF-1 expression inMecp2flox/y;MyoDiCre
muscle is conserved (Fig 4D) and no alteration of the P-rpS6 content is evident (Fig 4E). The
regeneration of the adultMecp2flox/y;MyoDiCre muscle is similar to that of control mice, and
Fig 1. Mecp2-/ymice exhibit skeletal muscle disorganization and atrophy. (A) Representative pictures of TA and brain of 6 weeks old WT andMecp2-/y
mice. Scale bars = 0,5 mm. (B) Measures of organ weights are indicated as means ± s.e.m. Unpaired t-test was performed and P values are shown.
Table also reports the percentage of reduction observed inMecp2-/ymice (n6), calculated considering WT values as 100%. (C) Representative TA and
gastrocnemius (Gast) muscle sections stained with H&E. Scale bar = 50 μm. (D) Representative TA and gastrocnemius muscle sections immunostained for
Laminin. Scale bar = 50 μm. (E) CSA analysis of single muscle fibers, showing the abundance of smaller fibers inMecp2-/ymice compared to WTmice. At
least 150 myofibers were counted for each animal/muscle, n = 3 per genotype. Left panel: quantification of mean CSA ± s.e.m. Significance is calculated with
t test (**, P value: 0.0059 for TA; **, P value: 0.0089 for Gast). Central and right panels: size distribution of single muscle fibers. x-Axis = fiber size (μm2); y-
Axis = percentage of fibers. (F) TA sections (n = 3) were stained with Sirius Red and the total amount of collagen was quantified with ImageJ (G); ns, P value:
0.5593. (H) Collagen ImRNA expression was assessed in WT andMecp2-/y gastrocnemius (n = 3). Significance is calculated with t test (ns, P value:
0.1126).
doi:10.1371/journal.pone.0130183.g001
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Fig 2. Mecp2-/ymuscles exhibit deregulated protein synthesis signalling pathways. (A) qPCR
evaluation of IGF-1 (n = 8) and IGF-R (n = 3) mRNA expression in WT andMecp2-/y gastrocnemius. All data
points were calculated in triplicate, normalized toGAPDH and represented as gene expression relative to WT
expression. Significance is calculated with t test (**** P value: <0.0001 for IGF-1; ns, P value: 0.7437 for
IGF-R). Data are represented as mean ± s.e.m. (B) ELISA assay quantifying IGF-1 protein levels onWT and
Mecp2-/y plasma and triceps (n = 6). All data points were calculated in duplicate. Significance is calculated
with t test (*, P value: 0.0313 and **, P value: 0.0096). Data are represented as mean ± s.e.m. (C)
Representative WB (left) and summary graph (right) of total rpS6 and phosphorylated rpS6 protein levels in
WT andMecp2-/y triceps lysates (n = 6). GAPDHwas included as loading control. Significance is calculated
MeCP2 Deficiency in Skeletal Muscle
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quantification of mean myofiber CSA 5 days after damage does not reveal statistically signifi-
cant differences (S3 Fig).
Overall, these results indicate that skeletal muscles do not directly require MeCP2 for devel-
opment and growth. Accordingly,Mecp2flox/y;MyoDiCre muscles are not hypotrophic, as indi-
cated by the similar skeletal muscle weight ofMecp2flox/y;MyoDiCre mice and controls at
various postnatal ages (S1 Table).
Discussion
So far, RTT research has focused mainly on the nervous system and genetic deletion studies
have shown that inactivation ofMecp2 in post-mitotic neurons leads to several symptoms com-
mon with those ofMecp2-null mice. However, the concept of RTT as an exclusively neuronal
disease is changing, therefore, highlighting the relevance of searching for tissue dysfunctions
associated with the absence of MeCP2.
RTT patients are characterized by a significant hypotonia; concordantly, theMecp2-null
mouse model is characterized by a decreased growth and severe hypotonia. Skeletal muscles
account for approximately 40% of the total body mass and represent a major player in energy
balance. Muscle fiber size changes physiologically in function of the environmental demand
and it adapts to the various pathological conditions. One of the main mechanisms of this
dynamics is the regulation of protein homeostasis obtained through the balance between pro-
tein synthesis and degradation [25]. Here we show that MeCP2 deficiency leads to a severe
muscle hypotrophy by regulating myofiber size in a non cell-autonomous way. Indeed, while
theMecp2-null mice are characterized by a reduced skeletal muscle mass, the novelMecp2flox/y;
MyoDiCre transgenic line, in whichMecp2 has been deleted only in myoblasts and skeletal mus-
cle fibers, does not show any of the RTT-like myopathy: in particular, weight and size of skele-
tal muscles do not differ from those of control littermates. Of relevance, this is the first genetic
mouse model in whichMecp2 has been ablated in a tissue different from the nervous system,
and our study suggests thatMecp2 is not directly required for proper development, growth and
regeneration of skeletal muscle.
The muscle phenotype observed in the null mice could be caused either by neuromuscular
plaque defects and/or by an altered crosstalk of paracrine/endocrine signaling. Previous elec-
tromyography studies on RTT patients have shown a normal corticospinal pathway [11], there-
fore dismissing the neuromuscular plaque as a major player in the observed MeCP2-linked
muscular phenotype. Accordingly, our analyses of the number and characteristics of the neuro-
muscular junctions did not reveal any overt difference inMecp2-null mice with respect to WT
littermates. Thus, altered growth signaling might determine the muscle defects characterizing
theMecp2-null mice.
The Growth Hormone (GH)/IGF1 axis is a critical regulator of somatic growth and other
developmental processes [26] via the production and secretion of hepatic IGF-1, which then
exerts its biological effects on the other tissues. One of the major target tissues is the skeletal
muscle, where IGF-1 is also produced and is an important regulator of mass both in basal con-
ditions and in response to exercise and muscle injury. IGF-1 administration toMecp2-null
mice ameliorates several RTT-features [12]. More importantly, it ameliorates certain breathing
and behavioral abnormalities in RTT girls [27]. Here, we have shown thatMecp2-null mice
with t test (*, P value: 0.0225; ns, P value: 0.1924). Data are represented as mean ± s.e.m. (D) qPCR
evaluation of BDNFmRNA expression in WT andMecp2-/yGast. All data points were calculated in triplicate,
normalized toGAPDH and represented relative to theWT expression (n = 5). Significance is calculated with t
test (*, P value: 0.0425).
doi:10.1371/journal.pone.0130183.g002
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have decreased IGF-1 protein levels both in plasma and skeletal muscle. The corresponding
mRNA levels are reduced in skeletal muscle, suggesting a local defective expression. In accor-
dance with decreased IGF-1 levels, we found that phosphorylation of rpS6 is significantly
reduced in the muscles ofMecp2-null mice. Since the levels of IGF-1 and rpS6 phosphorylation
are normal in theMecp2flox/y;MyoDiCre transgenic line, we suggest that this pathway regulated
by paracrine/endocrine factors is one of the major causes of the observed muscle hypotrophy.
During the past years, several genetic mouse models have been used to dissect the signaling
pathways involved in muscle-mass regulation and to identify strategies to affect the activity of
IGF1-Akt signaling [28]. Although perfectly aware of the vast number of interactions of the
IGF1-Akt pathway with others factors and molecular trails, we would like to highlight that in
adult skeletal muscle, hypertrophy can be induced by blocking myostatin through post-devel-
opmental myostatin gene knockout, with follistatin (a myostatin antagonist) or anti-myostatin
antibodies. Fiber size is also controlled by AMP-activated kinases and mTOR, while corticoste-
roids reduce the production of IGF1 [28]. Mouse models genetically modified in components
of these pathways (listed in ref. 28) might be used in future studies to understand the basis of
reduced muscle growth inMecp2-null mice.
In addition to IGF-1, skeletal muscle is the source of several myokines secreted by contract-
ing skeletal myocytes that can have an autocrine, paracrine or endocrine activity. Amongst
these, there is BDNF, whose circulating levels are determined by both skeletal muscle and brain
[29]. BDNF has been reported as a direct target of MeCP2 repression [30,31]; however, its lev-
els are reduced in the brain of RTT patients andMecp2mutant mice and treatment with BDNF
have been suggested as a therapeutic approach for RTT [32,33]. Here, we show that the expres-
sion of muscle derived Bdnf gene is also greatly reduced inMecp2-null mice.
Skeletal muscle homeostasis also depends on the ability of the tissue to initiate an extensive
repair process counteracting the loss of muscle mass and fibers, through the activation of myo-
genic stem cells, the satellite cells, in a regenerative process that recapitulate myogenesis [34].
Following acute muscle damage,Mecp2-null mice are able to regenerate new myofibers with
proper timing. However, and in accordance with the important reported hypotrophy, new
fibers maintain a smaller size with respect to the control littermates. Since muscle regeneration
and myofiber size are normal in mice with muscle specificMecp2 inactivation,Mecp2 appears
to be dispensable for myogenesis in satellite cells while the observed fiber growth defects in the
null animals depend on paracrine/endocrine signals. Indeed, IGF-1 levels remain low through-
out the entire regeneration process.
A well-timed inflammatory response and corresponding cytokine production is also crucial
for proper generation of new muscle fibers. Inflammatory macrophages infiltrate the acutely
injured tissue, secrete inflammatory signals, such as TNF-α, clear myofibers and undergo a
switch towards a reparatory program. At later times, alternatively activated macrophages accu-
mulate into injured muscles and actively sustain fiber reconstitution mainly by generating
Fig 3. Regeneration after acute muscle damage inMecp2-/y skeletal muscle. (A) Representative gastrocnemius cross-sections of WT andMecp2-/y
mice 5 days (left panels) and 10 days (right panels) after Ctx injury stained with Hematoxylin and Eosin or immunostained for Laminin/DAPI to recognize
centrally-nucleated myofibers. Scale bar = 100 μm. (B) Mean CSA ± s.e.m. and distribution of regenerating centronucleated myofibers 5 days (left panel) and
10 days (right panel) after Ctx injury. At least 150 myofibers were counted for each animal; significance is calculated with t test (****: p<0.0001). (C)
Quantification of the number of CD68+, CD86+ and CD206+ cells located in the damaged area of WT andMecp2-/y gastrocnemii 5 days after Ctx injury.
Significance is calculated with t test (ns, CD68+: P value 0.8650; CD86+: P value 0.3513; CD206+: P value 0.7421. n3). Data are represented as mean ± s.
e.m. (D) qPCR evaluation of IL-6, TNF-α, iNOS, IL-10 and IGF-1mRNA in quadriceps 2, 5, 10 days after Ctx injury of WT and Mecp2-/ymice. All data points
were calculated in triplicate, normalized toGAPDH and expressed as relative to not injuredWT expression. Each time point is compared to the No Ctx
situation of the same genotype and significance is calculated with t test. Data are represented as mean ± s.e.m. (IL-6 P value: ** = 0,0027, * = 0,0277; TNF-α
P value: ** = 0,0033, * = 0,0195, ****<0,0001; iNOS P value: * = 0.0215, * = 0,0443, * = 0,0210; IL-10 P value: ** = 0,0089, *** = 0,0009, ****<0,0001;
IGF-1 P value: * = 0,0477, * = 0,0191; n = 3).
doi:10.1371/journal.pone.0130183.g003
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Fig 4. Muscle specific deletion ofMecp2 does not lead to the observedmuscular alterations. (A) WBs confirm the specific skeletal muscle deletion of
Mecp2 in the transgenicMecp2FloxMyoDiCremice. WT,Mecp2Flox andMyoDiCre genotypes are used as controls. (B) Representative TA cross-sections
stained with Hematoxylin and Eosin (upper panels) or immunostained for Laminin (bottom panels). Scale bar = 50 μm. (C) Mean CSA ± s.e.m. showing no
statistically significant differences betweenMecp2FloxMyoDiCremice fibers and control ones. At least 130 myofibers were counted for each animal.
Significance was calculated using one-way ANOVA (ns: 0.8520). (D)Mecp2FloxMyoDiCremice and controls show similar levels of Gast IGF-1mRNA.
Significance was calculated using one-way ANOVA (n3; ns: 0.9283). (E) Graph showing similar levels of P-rpS6 betweenMecp2FloxMyoDiCre quadriceps
and the corresponding controls. Data are represented as mean ± s.e.m. (n = 2).
doi:10.1371/journal.pone.0130183.g004
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signals with trophic functions, such as IGF-1 or IL-10. In the muscles ofMecp2-null mice, infil-
tration of macrophages appears to occur properly, and the balance between inflammatory and
alternatively activated macrophages is similar with respect to control mice. Nevertheless, when
we compared the kinetics of expression of several cytokines, we found thatMecp2-null muscles
show a delayed appearance of both inflammatory and anti-inflammatory signals after damage,
with the notable exception of IGF-1, whose expression levels are always lower in the MeCP2
deficient mice. These results suggest that altered kinetics of activation of cytokines and macro-
phage markers may contribute, together with the global IGF-1 deficiency, to the regenerating
fiber growth defect. Of note, while we were revising this manuscript, it has been demonstrated
thatMecp2 is expressed and required by macrophages for a proper response to inflammatory
stimuli [35]. The authors have suggested that theMecp2-null macrophage altered responsive-
ness to environmental stimuli might affect tissue homeostasis, therefore contributing to RTT
clinical features occurring in multiple organ systems. Since macrophages have been proposed
as one of the major source of IGF-1 [36] and the functional interference with IGF-1 is known
to influence the characteristics of the inflammatory response in skeletal muscle [37,38], we
raise the possibility that the observed altered response to muscular injury and the IGF-1 defi-
ciency might be causally related. Further studies are necessary to address this contention.
In conclusion we have demonstrated that a general deficiency of MeCP2 causes an impor-
tant muscle hypotrophy that is probably the main cause of hypotonia characterizing most RTT
patients. This defect appears to be mostly due to non cell-autonomous mechanisms related to
paracrine/endocrine signaling and to the synthesis of trophic factors such as IGF-1 and BDNF.
The fact that the down-regulation of these trophic factors, as reported in previous literature
and herein, does not depend directly on MeCP2 deficiency, underscores the relevance of identi-
fying the upstream molecular pathway(s) causing this common alteration. Restoring this path-
way(s) might, in fact, represent a more effective therapeutic strategy with respect to directly
altering BDNF or IGF-1 levels.
Materials and Methods
Animals
Mecp2-null males (Mecp2-/y) B6.129P2(C)Mecp2tm1.1 Bird/J [10] together with the WT C57BL/
6J controls were obtained by crossing heterozygous females (Mecp2-/+) to WT C57BL/6J males.
This mouse line was housed at Charles River (Calco, Lecco, Italy). The muscle-specificMecp2-
conditional mouse line was obtained by crossing C57BL/6JMecp2flox/+ [10] with FVB-Tg
MyoDiCre mice [23]. Breeding of this mouse line was done in the animal facility at San Raffaele
Scientific Institute. All experimental protocols were approved by the San Raffaele Scientific
Institutional Animal Care and Use Committee (IACUC 355, 489, 450 and 610) in accordance
with the Italian law.
Animals were anesthetized with 2-Bromo-2-chloro-1,1,1-trifluoroethane or Avertin and
sacrificed by cervical dislocation. All efforts were made to minimize suffering.
Organs and body weight analysis
Vital organs such as heart, kidneys, liver, lung and spleen were recovered. All of them were
observed macroscopically and their appearance was compared between the different genotypes.
Body and organs weights were measured and recorded.
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Acute muscle damage
Animals were anaesthetized by inhalation with 2-bromo-2-chloro-1,1,1-trifluoroethane,99%
(B4388-125ML, Sigma-Aldrich, Saint Louis, MO, USA) and subsequently injected with Ctx
(obtained from Naja mossambica mossambica snake, C9759 Sigma-Aldrich): 50 μl Ctx 10μM
for WT andMecp2-/y quadriceps and gastrocnemii; 50 μl Ctx 15μM forMecp2flox/yMyoDiCre
and controls tibialis anterior (TA). Mice were sacrificed and muscles harvested 2, 5 or 10 days
after injection.
qPCR
Total RNA was isolated from gastrocnemii or quadriceps using the RNeasy Fibrous Tissue
Mini Kit (74704, QIAGEN, GmbH, Germany) as instructed by the manufacturer. Extracted
RNA was quantified with NanoDrop (ND-1000 Spectrophotometer EuroClone, Milan, Italy)
and its quality was assessed through a denaturing 1% agarose gel with EtBr. Complementary
DNA (cDNA) was transcribed using the RT2 First Strand Kit (330401, QIAGEN) according to
the manufacturer’s instructions. PCR reactions were run on a StepOnePlus Real-Time PCR
System (Applied Biosystems, Waltham, MA, USA), using SYBR Select Master Mix (4472908,
Applied Biosystems) and primers (200 nM). ΔCt were calculated using GAPDH as normalizer.
Gene expression was represented as relative to the WT one.
Primers list: GAPDH: Fwd: 5’-CACCATCTTCCAGGAGCGAG-3’, Rev: 5’-CCTTCTCCAT
GGTGGTGAAGAC-3’; Collagen I: Fwd: 5’-GCTCCTCTTAGGGGCCACT-3’, Rev: 5’-CCAC
GTCTCACCATTGGGG-3’; IGF-1: Fwd: 5’-CTCTGCTTGCTCACCTTCAC-3’, Rev: 5’-CT
CATCCACAATGCCTGTCT-3’; IGF-1R:
Fwd: 5’-ACACCAGGAACAACGGAGAG-3’, Rev 5’-AGGCAGGTCTACATCCACCA-3’;
BDNF: Fwd: 5’-AAGTCTGCATTACATTCCTCGA-3’; Rev: 5’-TTATCAATTCACAATTAA
AGCAGCAT-3’; IL-6: Fwd: 5’-CTCTGCAAGAGACTTCCATCCAGT-3’, Rev: 5’-CGTGGTT
GTCACCAGCATCA-3’; TNF-α: Fwd: 5’-TCCCAGGTTCTCTTCAAGGGA-3’, Rev: 5’-
GGTGAGGAGCACGTAGTCGG-3’; iNOS: Fwd: 5’-AGCCAAGCCCTCACCTACTT-3’, Rev:
5’-TCTCTGCCTATCCGTCTCGT-3’; IL-10: Fwd: 5’-ATTTGAATTCCCTGGGTGAGAAG-
3’, Rev: 5’-CACAGGGGAGAAATCGATGACA-3’
Western Blotting
Muscles and organs fromMecp2-/y,Mecp2flox/yMyoDiCre and controls were homogenized with
Ultra-Turrax (by IKA) in lysis buffer (EDTA 5mM, NaCl 350 mM, Triton X-100 1%, Glycerol
10%, NaF 50 mM, Tris-HCl pH 7.5 20 mM) with PhosSTOP 1X (04906837001, Roche, Basel,
Switzerland) and cOmplete EDTA-free protease inhibitor cocktail (11873580001, Roche). Sol-
uble proteins were quantified with Pierce BCA Protein Assay Kit (23227, Thermo Scientific,
Waltham, MA, USA). Protein were electrophoresed on 10% SDS-polyacrylamide gel and blot-
ted onto nitrocellulose using the Trans-Blot Turbo Transfer System from Bio-Rad (11 min, 2.5
A, 25 V) and probed with the following primary antibodies: anti-S6 ribosomal protein 5G10
1:1000 (2217, Cell Signaling, Boston, MA, USA), anti-phospho S6 ribosomal protein (Ser240/
244) 1:1000 (2215, Cell Signaling), anti-MeCP2 D4F3 1:1000 (3456, Cell Signaling), anti-
GAPDH 1:1000 (TAB1001 Thermo Scientific). For Fig 2C, membranes were incubated with
the anti-rabbit secondary antibody AlexaFluor 488 (1:2000, A21206 Life Technologies, Boston,
MA, USA), then fluorescent bands were detected and visualized using the laser scanner
Typhoon FLA 9000 (GE Healthcare, Buckinghamshire, UK). For Fig 4A, HRP-conjugated
anti-rabbit secondary antibodies were used (31460, 1:10000, Thermo Scientific) and blots were
visualized using a chemiluminescence-based detection system (SuperSignal West Pico Chemi-
luminescent Substrate, Thermo Scientific). For quantitative measurement, blots were analyzed
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with ImageJ, normalizing band intensities to GAPDH levels. To evaluate rpS6 phosphorylation
we made a ratio between the normalized phospho-protein and the normalized total isoforms of
the same protein.
ELISA Assay
To determinate Insulin-like Growth Factor I (IGF-1) concentrations in plasma and triceps
homogenates of 6 weeks old WT andMecp2-/y mice, we employed the Quantikine ELISA
Mouse/Rat IGF-1 Immunoassay (MG100, R&D Systems, Minneapolis, MN, USA), according
to the manufacturer’s instructions. Optical density was determined using the VersaMax Tun-
able Microplate Reader.
Histology and Immunofluorescence
Muscles were collected and embedded in OCT or directly frozen in liquid nitrogen cool isopen-
tane. 8 micron serial muscle sections were stained with Hematoxylin and Eosin (H&E) (Sigma-
Aldrich) and Sirius Red (Sigma-Aldrich) according to standard procedures. For quantification
of Sirius Red areas the images were subsequently analyzed using the batch mode of the ImageJ
vs 1.48 macro. This macro was written to quantify the percentage of fibrosis compared to the
total amount of tissue within an image. The color threshold algorithm used by this macro is
based on an algorithm written by G. Landini (version v1.8) available at [www.mecourse.com/
landinig/software/software.htm].
Immunofluorescence on frozen section muscles were generally carried out as in [39]. For
macrophages and fiber type specific antibodies, muscle sections were fixed with 4% parafor-
maldehyde in PBS. After 10 minutes in glycine 0.1M, they were blocked for 1 hour in 5%
serum (FBS for CD68 staining, donkey serum for CD86 and CD206 staining, FCS for MHCI
and MHCIIB staining), 0.1% Triton X-100, 5% BSA solution in PBS before incubation with pri-
mary antibodies in a 5% BSA in PBS solution. Incubation was performed O.N. at 4°C.
Primary antibodies: chicken anti-laminin (1:500, Sigma-Aldrich), rabbit anti-synaptophysin
(1:500, Invitrogen, Boston, MA, USA), mouse anti-neurofilament (1:150, Sigma-Aldrich); tet-
ramethylrhodamine α-bungarotoxin (1:100 Invitrogen); rat anti-CD68 (1:150; AbD Serotec,
Bio Rad, Hercules, CA, USA), rat anti-CD206 (1:100; AbD Serotec), rat anti-CD86 (1:100;
BD-Pharmingen, Franklin Lakes, NJ, USA), mouse IgG2b anti-MHCI BAD5 (1:50), mouse
IgM anti-MHCIIB BF-F3 (1:50) [40,41]. Appropriate Alexa Fluor (Alexa 488 or Alexa 546)-
conjugated antibodies (1:500; Invitrogen) were used as second-step reagent. Nuclei were coun-
terstained with DAPI (1:1000, Sigma Aldrich) and mounted with Fluorescence Mounting
Medium (Dako, Glostrup, Denmark).
Measurement of myofiber cross sectional area (CSA)
Cross sectional area of the myofibers was calculated on Laminin stained section images
obtained from TA and Gast muscles of mice. Measurement of the area was performed using
the analyzer software ImageJ vs. 1.48.
Image acquisition and manipulation
Fluorescent and phase contrast images were taken using Nikon Eclipse E600 microscope.
Image acquisition was done using the Nikon digital camera DXM1200 and the acquisition soft-
ware Nikon ACT-1 (lenses Plan Fluor:X4/0.13, X10/0.33, X20/0.50, X40/0.75).
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Statistics
Statistical significance of variations among the different experimental groups was determined
by two-tailed Student's t test (Prism 5, GraphPad Software) or One-way ANOVA (Prism 5,
GraphPad Software). P values less than 0.05 were considered significant.
Supporting Information
S1 Fig. Muscle fiber type composition is similar between WT andMecp2-null mice. (A)
Representative WT andMecp2-null gastrocnemius muscle sections immunostained with
BAD5 and BF-F3 to recognize, respectively, fibers I (MHCI) and IIb (MHCIIB). Scale
bar = 50 μm. (B) Quantification of the number of type I and type IIb fibers. At least 200 myofi-
bers were counted for each animal, n = 3 per genotype. Data are represented as mean ± s.e.m.
Significance is calculated with t test (ns, P value: 0.9763).
(TIF)
S2 Fig. Density of neuromuscular junctions is similar between WT andMecp2-null mice.
Representative WT andMecp2-null tibialis anterior muscle sections stained with α-bungaro-
toxin, Ab against synaptophysin and neurofilament, DAPI. Scale bars = 50 μm
(TIF)
S3 Fig. Regeneration after acute muscle damage inMecp2FloxMyoDiCre skeletal muscle. (A)
Representative TA cross-sections ofMecp2FloxMyoDiCre and control mice 5 days after Ctx
injury, stained with Hematoxylin and Eosin or immunostained for Laminin and DAPI to rec-
ognize centrally-nucleated myofibers. Scale bar = 50 μm. (B) Mean CSA ± s.e.m. of regenerat-
ing centronucleated myofibers shows no statistically significant differences between the
different genotypes. At least 150 regenerating centrally-nucleated myofibers were counted for
each animal. Significance was calculated using one-way ANOVA (ns: 0.1116).
(TIF)
S1 Table. Weights of muscles and organs retrieved fromMecp2FloxMyoDiCre and control
mice at months 5 and 3, and 6 weeks of age. Each genotype was compared with the WT and
significance was calculated with t test ( p< 0,05,  p<0,01). Data are indicated as means ± s.e.
m. n = 4 per genotype at each time point.
(DOCX)
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